Flexion Therapeutics (FLXN) PT Raised to $28 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Flexion Therapeutics (FLXN) PT Raised to $35 at Northland Capital Markets
December 27, 2019 12:07 PM ESTNorthland Capital Markets analyst Carl Byrnes raised the price target on Flexion Therapeutics (NASDAQ: FLXN) to $35.00 (from $28.00) while maintaining a Outperform rating.
... MoreFlexion Therapeutics (FLXN) PT Raised to $29 at Craig-Hallum
December 27, 2019 8:37 AM ESTCraig-Hallum analyst Frank Brisebois raised the price target on Flexion Therapeutics (NASDAQ: FLXN) to $29.00 (from $24.00) while maintaining a Buy rating.
... MoreBMO Capital Reiterates $29 PT on Flexion Therapeutics (FLXN)
December 27, 2019 7:37 AM ESTBMO Capital analyst Gary Nachman reiterated an Outperform rating and $29.00 price target on Flexion Therapeutics (NASDAQ: FLXN).
The analyst comments "FDA approved FLXN's sNDA to revise Zilrettas label, importantly modifying limitation of use (LoU) language that should help allay some concerns regarding... More
Needham & Company Reiterates $36 PT on Flexion Therapeutics (FLXN)
December 27, 2019 7:34 AM ESTNeedham & Company analyst Serge Belanger reiterated a Buy rating and $36.00 price target on Flexion Therapeutics (NASDAQ: FLXN).
The analyst comments "Overall, we believe FLXN achieved its key goal of removing the LOU, which was a source of confusion for many... More
